At the same time, we need to be working through reimbursement processes, that's time consuming, we're utilizing name patient sales approvals in markets where it's appropriate that's been successful, but time consuming as well. So the combination of those factors are part of and the rarity of CLN2 is really the picture of a slow revenue ramp. Having said that, we expect, as was noted in the prepared remarks that we will make slow, but steady progress on revenue and that Brineura will be a more meaningful revenue contributor going forward.